154 related articles for article (PubMed ID: 29750649)
1. Cardiac examination in children with Laron syndrome undergoing mecasermin therapy.
Erol N; Yıldız M; Güven A; Yıldırım A
J Pediatr Endocrinol Metab; 2018 Jun; 31(6):675-679. PubMed ID: 29750649
[TBL] [Abstract][Full Text] [Related]
2. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF
BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
[TBL] [Abstract][Full Text] [Related]
4. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.
Scheinowitz M; Feinberg MS; Laron Z
Growth Horm IGF Res; 2009 Jun; 19(3):280-2. PubMed ID: 19117781
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome.
Bang P; Woelfle J; Perrot V; Sert C; Polak M
Eur J Endocrinol; 2021 Feb; 184(2):267-276. PubMed ID: 33434161
[TBL] [Abstract][Full Text] [Related]
6. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome.
Konen O; Silbergeld A; Lilos P; Kornreich L; Laron Z
J Pediatr Endocrinol Metab; 2009 Mar; 22(3):235-9. PubMed ID: 19492579
[TBL] [Abstract][Full Text] [Related]
7. Postprandial hyperglycemia corrected by IGF-I (Increlex®) in Laron syndrome.
Latrech H; Simon A; Beltrand J; Souberbielle JC; Belmejdoub G; Polak M
Horm Res Paediatr; 2012; 78(3):193-200. PubMed ID: 22986916
[TBL] [Abstract][Full Text] [Related]
8. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Williams RM; McDonald A; O'Savage M; Dunger DB
Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):311-24. PubMed ID: 18363546
[TBL] [Abstract][Full Text] [Related]
9. Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency.
Silbergeld A; Lilos P; Laron Z
J Pediatr Endocrinol Metab; 2007 Dec; 20(12):1325-8. PubMed ID: 18341092
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
Laron Z
Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
Tonella P; Flück CE; Mullis PE
Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus with Laron syndrome: case report.
Agladıoglu SY; Cetınkaya S; Savas Erdeve S; Onder A; Kendırcı HN; Bas VN; Aycan Z
J Pediatr Endocrinol Metab; 2013; 26(9-10):955-8. PubMed ID: 23729552
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.
Petriczko E; Jackowski T; Horodnicka-Józwa A; Wikiera B; Noczyńska A; Korpal-Szczyrska M; Birkholz-Walerzak D; Małecka-Tendera E; Kalina-Fraska B; Kalina M; Barg E; Beń-Skowronek I; Szewczyk L; Hilczer M; Smyczyńska J; Stawerska R; Lewiński A; Ziora K; Bossowski A; Pietrewicz E; Pyrżak B; Kędzia A; Szalecki M; Kilian A; Walczak M
Endokrynol Pol; 2019; 70(1):20-27. PubMed ID: 30351442
[TBL] [Abstract][Full Text] [Related]
15. Obese adults with primary growth hormone resistance (Laron Syndrome) have normal endothelial function.
Shechter M; Ginsberg S; Scheinowitz M; Feinberg MS; Laron Z
Growth Horm IGF Res; 2007 Apr; 17(2):165-70. PubMed ID: 17320443
[TBL] [Abstract][Full Text] [Related]
16. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
[TBL] [Abstract][Full Text] [Related]
17. Further observations on the effects of long-term treatment with recombinant human insulin-like growth factor 1 in growth hormone insensitivity syndrome.
El Kholy M; Amr NH; Elsedfy H
Horm Res Paediatr; 2014; 81(4):258-65. PubMed ID: 24642532
[TBL] [Abstract][Full Text] [Related]
18. Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome.
Bourla DH; Laron Z; Snir M; Lilos P; Weinberger D; Axer-Siegel R
Ophthalmology; 2006 Jul; 113(7):1197.e1-5. PubMed ID: 16815402
[TBL] [Abstract][Full Text] [Related]
19. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.
Bisker-Kassif O; Kauli R; Lilos P; Laron Z
Obes Res Clin Pract; 2014; 8(1):e55-62. PubMed ID: 24548577
[TBL] [Abstract][Full Text] [Related]
20. Investigational agents for the treatment of growth hormone-insensitivity syndrome.
Kemp SF; Thrailkill KM
Expert Opin Investig Drugs; 2006 Apr; 15(4):409-15. PubMed ID: 16548790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
